Drug intelligence / Profile preview

AGMB-102

Development stage: Unknown
Lead developer: Agomab Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AGMB-102 is a monoclonal antibody developed by Agomab Therapeutics. It functions as a partial agonist of the c-Met receptor (also known as the hepatocyte growth factor receptor), mimicking some effects of hepatocyte growth factor (HGF). The drug is designed for potential use in treating fibrotic and inflammatory diseases, leveraging HGF’s regenerative properties to promote tissue repair and modulate fibrosis. Unlike its related candidate AGMB-101, which is a full c-Met agonist, AGMB-102 only partially activates the MET receptor. As of June 2025, AGMB-102 remains in the discovery stage and has not yet entered clinical trials[1][2][5][6][7][8].

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on AGMB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGMB-102.

Explore the full profile